Trials / Completed
CompletedNCT00089999
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients With Advanced or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II study will evaluate and compare the efficacy and tolerability of two dose schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with advanced or metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lapatinib |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2004-08-23
- Last updated
- 2017-02-28
- Results posted
- 2014-08-29
Locations
31 sites across 11 countries: United States, Chile, Hong Kong, India, Malaysia, Mexico, Pakistan, Peru, Poland, Singapore, Taiwan
Source: ClinicalTrials.gov record NCT00089999. Inclusion in this directory is not an endorsement.